Therapeutic Efficacy of Injectable Hydrogel Systems in Mice Tumor Models

Background: This study explored the use of a 3D hydrogel, a tissue-engineering method designed to enhance stromal lymphoid cell therapy and boost the immune response of antibodies. Mouse models of two tumor types—B16F10 melanoma and MC-38 colorectal carcinoma—were used in two separate studies to assess the in vivo immune response to this approach.Methods: In the B16F10 melanoma study, 42 mice were randomized into six groups: Group 1, saline; Groups 2 &3, escalating doses of anti-cytotoxic T-lymphocyte-associated protein 4(anti-CTLA4 and anti-programmed death 1( anti-PD-1) antibodies; Group 4, combination of hydrogel, inhibitors, and fibroblastic reticular cells (FRCs); Group 5, 3D hydrogel, FRCs, and cytokines; Group 6, hydrogel, checkpoint inhibitors, FRCs, and cytokines.In the MC-38 colorectal carcinoma study, 100 mice were randomized into ten groups: Group 1, saline; Groups 2 to 4, escalating doses of anti-CTLA4 and anti-PD-1 antibodies; Groups 5 to 7, the same escalating doses combined with a 3D hydrogel; Groups 8 to 10, higher doses combined with a 3D hydrogel, along with the addition of FRCs.Results: Hydrogel capsules harvested five days post-injection revealed lymph node-like structures. Mice treated with FRCs and biologics in 3D hydrogel showed a remarkable increase in survival rate and complete response. Conclusion: The study highlights the potential of 3D hydrogels to improve immunotherapy. While promising survival outcomes were observed in animal models, further research is needed to confirm these findings in humans. The results support the approach’s clinical potential and lay the groundwork for future advancements in cancer treatment.